MUC16 and cancer: On the other hand, it turned out that Meso64-TR3 and TR3 were functionally indistinguishable on MUC16-negative cancer cells (Jurkat and other, nearly MUC16-negative cancer cells, such as BxPC3), while Meso-TR3 showed a markedly reduced activity profile on these cells, in accordance with its previously proposed prodrug feature [28].